List view / Grid view
Drug discovery research is funded primarily by government and by philanthropic groups. Later development is funded mainly by pharmaceutical companies.
The global network of centers will investigate where pathogens emerge and how they adapt to cause disease in humans, in the hopes of increasing our preparedness for future disease outbreaks.
The UK government will invest £8.4 million in COVID-19 research projects to reveal more information that can be used to develop therapies and vaccines against the disease.
The UK National Institute of Health Research (NIHR) and UK Research and Innovation (UKRI) wish to fund research exploring if people from black, Asian and middle eastern backgrounds are disproportionately at risk from COVID-19.
A study has shown that the COVID-19 pandemic has resulted in a high level of research donations, making the condition the third most funded disease on average by year.
A total of 21 COVID-19 research projects have been granted funding by the UK government, including vaccine and therapeutic development.
Drug Target Review rounds up the latest announcements regarding funding for research into COVID-19 treatments and vaccines.
The National Drug Discovery Centre (NDDC) has opened in Australia, with support from the government to subsidise the screening of medicinal compounds.
Researchers have found that half of public and charity support for health research over the past 14 years has been for studying the cause and progression of disease.
Researchers have developed a new body-on-chip technology that can demonstrate the pharmacokinetics and pharmacodynamics of drugs in a pre-clinical setting without the need for animal testing.
The CEPI has announced three respective projects with Inovio, the University of Queensland and Moderna, to develop a vaccine for the novel coronavirus, nCoV-2019.
Research suggests that over half of the total $5.2bn investment for artificial intelligence in pharma went to drug design applications in 2019, but overall investment is slowing.
Researchers have revealed that small- and medium-sized companies will by key in the growth of the life sciences sector in Scotland.
Professor Sir John Bell, Regius Professor of Medicine at the University of Oxford, delivered a speech at the MHRA’s 14th Annual Lecture in London, outlining his vision for the UK life sciences industry. Here, Nikki Withers summarises the key take-home messages from the talk, including how UK researchers and investors…
Charles River Laboratories International, Inc. (NYSE: CRL) announced that its team of neuroscience drug discovery experts will present 26 scientific posters, both independently and collaboratively with clients, at Neuroscience 2018, the 48th annual meeting of the Society for Neuroscience (SfN)...
The NIH is supporting efforts to broaden biomedical scientists’ access to cryo-electron microscopy the imaging method that is revolutionising structural biology...
